Author: Humacyte, Inc

Posted Date:

May 8, 2026

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Humacyte, Inc

May 8, 2026
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

Humacyte, Inc

April 27, 2026
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Humacyte, Inc

April 24, 2026
Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Humacyte, Inc

April 22, 2026
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

Humacyte, Inc

April 21, 2026
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Humacyte, Inc

March 27, 2026
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

Humacyte, Inc

March 26, 2026
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

Humacyte, Inc

March 23, 2026
Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia

Humacyte, Inc

March 19, 2026
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Humacyte, Inc

March 19, 2026